SOLID BIOSCIENCES INC. Shares of Common Stock (par value $0.001 per share) AMENDED AND RESTATED SALES AGREEMENTSales Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
Solid Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
SOLID BIOSCIENCES INC. Restricted Stock Unit Agreement Granted under 2024 Inducement Stock Incentive PlanRestricted Stock Unit Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
SOLID BIOSCIENCES INC. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances)
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EXECUTIVE CHAIR AGREEMENTExecutive Chair Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Executive Chair Agreement (together with Exhibit A, the “Agreement”), effective January 1, 2022 (the “Effective Date”), is by and between Ian F. Smith, an individual having an address at 45 Commonwealth Avenue, Unit 3, Boston, MA 02116 (the “Executive Chair”), and Solid Biosciences Inc., a Delaware corporation (together with its affiliates, the “Company”), having an address at 141 Portland Street, Fifth Floor, Cambridge, MA 02139.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement is entered into as of this 3rd day of August, 2017 (the “Effective Date”), by and between Solid Biosciences, LLC, a company organized under the laws of Delaware and having an address at 161 First Street, Suite #300, Cambridge, MA 02142 (“Licensee”) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
SOLID BIOSCIENCES INC. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2024 Inducement Stock Incentive PlanNonstatutory Stock Option Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXCLUSIVE PATENT...Exclusive Patent License Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Washington
This exclusive patent license agreement (“Agreement”) is dated and effective as of the date of last signature (the “Effective Date”), and is made between the University of Washington, a public institution of higher education and an agency of the state of Washington, acting through UW CoMotion (“University”), and Solid GT, LLC, a limited liability company under the laws of the state of Delaware (“Company”), (individually “Party” or collectively “Parties”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LIFE TECHNOLOGIES CELL...Cell Line License Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • California
This CELL LINE LICENSE AGREEMENT (the “AGREEMENT” or the “LICENSE”), effective as of November 20, 2016 (the “EFFECTIVE DATE”), by and between Life Technologies Corporation, a Delaware corporation having its principal place of business at 5781 Van Allen Way, Carlsbad, CA 92008 USA (“LICENSOR”), and Solid Biosciences, a Delaware limited liability company having its principal place of business at 161 Third Street, Third Floor, Cambridge, MA 02142 (“LICENSEE”). Each of LICENSOR and LICENSEE may be referred to herein as a “PARTY” and collectively as the “PARTIES”.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • Missouri
THIS LICENSE AGREEMENT (“AGREEMENT”) is made and entered into this 15th day of October 2015 (“EFFECTIVE DATE”), by and between THE CURATORS OF THE UNIVERSITY OF MISSOURI, a public corporation of the State of Missouri (“UNIVERSITY”) and Solid GT, LLC having offices at One Broadway Street, Cambridge, MA 02142 (“LICENSEE”). UNIVERSITY and LICENSEE may sometimes be referred to herein as a “PARTY” or “PARTIES” as the case may be.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. PATENT LICENSE AGREEMENTPatent License Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances)
This Agreement is effective as of March 10, 2016 (the “EFFECTIVE DATE”), between Solid GT, LLC (“LICENSEE”) having the address in Article 12 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (“MICHIGAN”) having the address in Article 12 below. LICENSEE and MICHIGAN hereby agree as follows:
